Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $1.44
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 17, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 30, 26 | Zaki Mohamed | officer: Chief Medical Officer | A-Award | 213,900 | — |
Daily · Wilder smoothing
| Guggenheim |
| maintain |
| Buy |
| Buy |
| Jun 8, 26 | HC Wainwright & Co. | downgrade | Buy | Neutral |
| Jun 4, 26 | RBC Capital | downgrade | Outperform | Sector Perform |
| May 5, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 5, 26 | RBC Capital | maintain | Outperform | Outperform |
| Mar 23, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 16, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 13, 25 | Guggenheim | maintain | Buy | Buy |
| Jun 20, 25 | RBC Capital | maintain | Outperform | Outperform |
| Jun 30, 26 |
| Graham Peter J |
| officer: Chief Legal Officer |
| A-Award |
| 221,100 |
| — |
| Jun 30, 26 | Carmona Jose | officer: Chief Financial Officer | A-Award | 203,700 | — |
| Jun 30, 26 | Mallik Ameet | director, officer: Chief Executive Officer | A-Award | 675,000 | — |
| Mar 31, 26 | Redmile Group, Llc | 10 percent owner | S-Sale | 196,229 @ $3.75 | $736.3K |
| Apr 1, 26 | Redmile Group, Llc | 10 percent owner | S-Sale | 169,265 @ $3.80 | $643.0K |
| Mar 31, 26 | Redmile Group, Llc | 10 percent owner | S-Sale | 188,407 @ $3.75 | $706.9K |
| Apr 1, 26 | Redmile Group, Llc | 10 percent owner | S-Sale | 162,517 @ $3.80 | $617.4K |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 51.65 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 51.54 | Oscillator | Neutral |
| Williams %R (14) | -64.18 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.08 (Hist -0.01) | Oscillator | Sell |
| Average Directional Index (14) | 23.75 (+DI 24.9 / -DI 16.9) | Trend | Buy |
| EMA 20 | 1.44 | MA | Buy |
| SMA 20 | 1.43 | MA | Buy |
| EMA 50 | 1.37 | MA | Strong Buy |
| SMA 50 | 1.25 | MA | Strong Buy |
| SMA 200 | 2.53 | MA | Strong Sell |
Stock news · updated daily
$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029 HealthCare Royalty financing agreement amended, removing change-of-control payment Senior secure loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity LAUSANNE, Switzerland, Oct. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, and increase strategic optionality to maximize shareholder value while extending the expected cash runway into 2029. The strategic initiative includes securing new equity financing, restructuring the HealthCare Royalty (HCR) agreement, and reducing the outstanding loan principal.
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, NY, on Friday, September 11, 2026, at 9:10 a.m.
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment's commercial performance remained broadly consistent with recent quarters.
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago.
Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026 LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 13, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2026, and provided recent operational updates.
LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, August 13, 2026, at 8:30 a.m. EDT to report financial results for the second quarter of 2026 and provide operational updates.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.22 | -0.11 | Beat 49.1% | $19.25M |
| May 4, 2026 | -0.19 | -0.21 | Miss -10.5% | $20.85M |
| Mar 10, 2026 | -0.32 | -0.04 | Beat 87.5% | $23.06M |
| Nov 10, 2025 | -0.40 | -0.30 | Beat 25.0% | $16.43M |
| Aug 12, 2025 | -0.36 | -0.50 | Miss -38.9% | $18.84M |
| May 14, 2025 | -0.38 | -0.36 | Beat 5.3% | $23.03M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 13, 2026 | 2026-10-13 06:26:29 | View |
| SC 13G | Aug 14, 2026 | 2026-08-14 16:34:13 | View |
| S-8 | Aug 13, 2026 | 2026-08-13 16:44:05 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:10:05 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 09:14:34 | View |
| SC 13G | Jul 27, 2026 | 2026-07-27 16:25:22 | View |
| 4 | Jul 2, 2026 | 2026-07-02 17:17:13 | View |
| 4 | Jul 2, 2026 | 2026-07-02 17:16:41 | View |
| 4 | Jul 2, 2026 | 2026-07-02 17:16:03 | View |
| 4 | Jul 2, 2026 | 2026-07-02 17:15:30 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | ADCT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -2.2x | -2.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.9x | EPS est. -0.75 | In line |
| Price / Book | -1.0x | 1.8x | Discount |
| Price / Sales | 2.3x | 11.5x | Discount |
| EV / EBITDA | -4.4x | -2.8x | Elevated |
| Return on equity | 44.6% | — | Top tier |
| Gross margin | 88.7% | 94.6% | In line |
| Debt / Equity | -1.83 | -0.27 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -8.23 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure